• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Oxaprozin dose proportionality.

作者信息

Chiang S T, Lasseter K C, Fluck E R, Janssen F W, Leelavathi D, Hubsher J A

出版信息

J Clin Pharmacol. 1984 Nov-Dec;24(11-12):515-22. doi: 10.1002/j.1552-4604.1984.tb02761.x.

DOI:10.1002/j.1552-4604.1984.tb02761.x
PMID:6511991
Abstract

Twelve normal subjects each received single 300-, 600-, and 1200-mg oral doses of oxaprozin according to a three-period crossover design. Total drug plasma concentrations did not increase in proportion to the dose administered. Total clearance (CIo) and volume of distribution (Vd) increased with dose, though elimination t1 2 remained unchanged. The fraction of unbound oxaprozin in plasma (fup) varied linearly with total plasma concentration: it increased from 0.068 per cent at 10 micrograms/ml to 0.180 per cent at 170 micrograms/ml. A parameter fup was therefore introduced to express the average degree of unbound drug plasma for a given dose, and to allow the calculation of unbound volume of distribution (Vdu) and intrinsic clearance (CIi) as if binding were constant. Even though fup increased with dose, the overall binding in the body (fub approximately 0.52 per cent) was relatively stable. Neither Vdu nor CIi changed with dose; hence, unbound oxaprozin kinetics can be considered to be linear. Protein binding had no effect on unbound oxaprozin plasma levels within the given dose range, and there was a one-to-one proportionality between the dose administered and the unbound drug concentration in plasma.

摘要

相似文献

1
Oxaprozin dose proportionality.
J Clin Pharmacol. 1984 Nov-Dec;24(11-12):515-22. doi: 10.1002/j.1552-4604.1984.tb02761.x.
2
Inverse nonlinear pharmacokinetics of total and protein unbound drug (oxaprozin): clinical and pharmacokinetic implications.总药物及蛋白结合游离型药物(奥沙普秦)的非线性反相药代动力学:临床及药代动力学意义
J Clin Pharmacol. 1996 Nov;36(11):985-97. doi: 10.1177/009127009603601102.
3
Protein binding and clearance of oxaprozin, a highly bound anti-inflammatory agent.
Agents Actions. 1982 Apr;12(1-2):211-5. doi: 10.1007/BF01965148.
4
Oxaprozin disposition in renal disease.肾病中恶丙嗪的处置
Clin Pharmacol Ther. 1982 Apr;31(4):509-15. doi: 10.1038/clpt.1982.68.
5
Effect of chronic renal failure on oxaprozin multiple-dose pharmacokinetics.慢性肾衰竭对奥沙普秦多剂量药代动力学的影响。
Clin Pharmacol Ther. 1988 Sep;44(3):303-9. doi: 10.1038/clpt.1988.154.
6
Clinical pharmacokinetics of oxaprozin.奥沙普秦的临床药代动力学
Clin Pharmacokinet. 1998 Dec;35(6):425-36. doi: 10.2165/00003088-199835060-00002.
7
Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics.奥沙普秦和吡罗昔康,两种半衰期较长的非甾体抗炎药:蛋白结合差异对稳态药代动力学的影响。
J Clin Pharmacol. 1997 Apr;37(4):267-78. doi: 10.1002/j.1552-4604.1997.tb04302.x.
8
Metabolism and kinetics of oxaprozin in normal subjects.
Clin Pharmacol Ther. 1980 Mar;27(3):352-62. doi: 10.1038/clpt.1980.47.
9
Effects of food on oxaprozin bioavailability.
J Clin Pharmacol. 1984 Aug-Sep;24(8-9):381-5. doi: 10.1002/j.1552-4604.1984.tb02790.x.
10
Effects of oxaprozin alone or in combination with aspirin on hemostasis and plasma protein binding.恶丙嗪单独或与阿司匹林联合使用对止血和血浆蛋白结合的影响。
J Clin Pharmacol. 1983 Apr;23(4):139-46. doi: 10.1002/j.1552-4604.1983.tb02717.x.

引用本文的文献

1
Clinical pharmacokinetics of oxaprozin.奥沙普秦的临床药代动力学
Clin Pharmacokinet. 1998 Dec;35(6):425-36. doi: 10.2165/00003088-199835060-00002.
2
Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine.
Eur J Clin Pharmacol. 1986;31(3):371-4. doi: 10.1007/BF00981141.
3
Oxaprozin. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.奥沙普秦。对其药效学、药代动力学特性及治疗效果的初步综述。
Drugs. 1986 Oct;32(4):291-312. doi: 10.2165/00003495-198632040-00001.
4
Pharmacokinetics of oxaprozin in women receiving conjugated estrogen.奥沙普秦在接受结合雌激素治疗的女性中的药代动力学。
Eur J Clin Pharmacol. 1988;35(1):105-8. doi: 10.1007/BF00555518.